SCHEDULE: Vanguard Reports 6.53% Stake in Moderna

Vanguard Capital Management has disclosed beneficial ownership of 25,933,824 shares, representing 6.53% of Moderna Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, through its affiliates, now beneficially owns 25,933,824 shares of Moderna Inc. common stock.
• This holding represents 6.53% of the total class of securities.
• Vanguard has sole voting power over 3,061,366 shares and sole dispositive power over all 25,933,824 shares.
• The filing is made under Schedule 13G, indicating that Vanguard is not seeking to influence or change control of Moderna.
• The reporting date for this ownership stake is March 31, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, as it indicates significant institutional confidence from a major investor, though it is a passive filing and not an endorsement of immediate growth.

Positives

• Vanguard's significant stake suggests confidence in Moderna's long-term prospects.
• The filing indicates a passive investment approach, which is generally viewed positively by the market as it doesn't signal an activist intent.
• Vanguard's investment management includes various investment companies and managed accounts, indicating broad-based trust in Moderna.

Negatives

• The filing does not contain any negative financial or operational information about Moderna; it solely reports Vanguard's ownership.

Risks

• The primary risk for Moderna, as with any publicly traded company, is market volatility and potential shifts in investor sentiment.
• While not explicitly stated in this filing, Moderna's business is inherently tied to the success of its drug development pipeline and regulatory approvals, which carry inherent risks.

Future Outlook

This filing is a snapshot of ownership as of a specific date and does not contain forward-looking statements or guidance from Moderna Inc. itself. Vanguard's future outlook on Moderna would be reflected in potential future changes to their holdings.

Management Comments

• In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd.
• This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power.
• This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant institutional investor like Vanguard taking a substantial stake (6.53%) in a biotechnology company like Moderna is a strong signal of perceived long-term value and stability in the sector, particularly in the post-pandemic landscape where mRNA technology has proven its potential.

Stakeholder Impact

• Shareholders: The filing confirms a major institutional investor's significant passive stake, which can be seen as a stabilizing factor and a vote of confidence in the company's long-term value.
• Employees: Continued investment from large institutions can contribute to company stability, potentially supporting ongoing employment and research initiatives.
• Creditors: A stable shareholder base and institutional backing can positively influence a company's creditworthiness.

Next Steps

• Vanguard will continue to monitor its investment in Moderna.
• Moderna Inc. will continue its operations and development activities.

Key Dates

Keywords

Moderna, Vanguard, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology, Pharmaceuticals, SEC Filing